Choosing exercise or pharmacologic stress imaging, or exercise ECG testing alone: How to decide

Iskandrian AS, Heo J, Kong B, Lyons E. Effect of exercise level on the ability of thallium-201 tomographic imaging in detecting coronary artery disease: Analysis of 461 patients. J Am Coll Cardiol 1989;14:1477–86. Rozanski A, Gransar H, Hayes SW, Min J, Friedman JD, Thomson LE, et al. Temporal trends in the frequency of inducible myocardial ischemia during cardiac stress testing: 1991 to 2009. J Am Coll Cardiol 2013;61:1054–65. doi:10.1016/j.jacc.2012.11.056. Gharacholou SM, Pellikka PA. Trends in noninvasive testing for coronary artery disease: Less exercise, less information. Am J Med 2015;128:5–7. doi:10.1016/j.amjmed.2014.08.019. Argulian E, Po JR, Uretsky S, Kommaraju K, Suketukumar P, Agarwal V, et al. Comparison of the current reasons for undergoing pharmacological stress during echocardiographic and radionuclide stress testing. J Nucl Cardiol 2016. doi:10.1007/s12350-016-0398-2. Navare SM, Mather JF, Shaw LJ, Fowler MS, Heller GV. Comparison of risk stratification with pharmacologic and exercise stress myocardial perfusion imaging: A meta-analysis. J Nucl Cardiol 2004;11:551–61. Hachamovitch R, Kang X, Amanullah AM, Abidov A, Hayes SW, Friedman JD, et al. Prognostic implications of myocardial perfusion single-photon emission computed tomography in the elderly. Circulation 2009;120:2197–206. doi:10.1161/CIRCULATIONAHA.108.817387. Myers J, Prakash M, Froelicher V, Do D, Partington S, Atwood JE. Exercise capacity and mortality among men referred for exercise testing. N Engl J Med 2002;346:793–801. Bourque JM, Beller GA. Value of exercise ECG for risk stratification in suspected or known CAD in the era of advanced imaging technologies. JACC Cardiovasc Imaging 2015;8:1309–21. doi:10.1016/j.jcmg.2015.09.006. Bourque JM, Holland BH, Watson DD, Beller GA. Achieving an exercise workload of > or = 10 metabolic equivalents predicts a very low risk of inducible ischemia: Does myocardial perfusion imaging have a role? J Am Coll Cardiol 2009;54:538–45. doi:10.1016/j.jacc.2009.04.042. Bourque JM, Charlton GT, Holland BH, Belyea CM, Watson DD, Beller GA. Prognosis in patients achieving ≥ 10 METS on exercise stress testing: Was SPECT imaging useful? J Nucl Cardiol 2011;18:230–7. doi:10.1007/s12350-010-9323-2. Ross MI, Wu E, Wilkins JT, Gupta D, Shen S, Aulwes D, et al. Safety and feasibility of adjunctive regadenoson injection at peak exercise during exercise myocardial perfusion imaging: The Both Exercise and Regadenoson Stress Test (BERST) trial. J Nucl Cardiol 2013;20:197–204. doi:10.1007/s12350-013-9679-1. Partington SL, Lanka V, Hainer J, Blankstein R, Skali H, Forman DE, Di Carli MF, Dorbala S. Safety and feasibility of regadenoson use for suboptimal heart rate response during symptom-limited standard Bruce exercise stress test. J Nucl Cardiol 2012;19:970–8. doi:10.1007/s12350-012-9562-5. Dilsizian V, Gewirtz H, Paivanas N, Kitsiou AN, Hage FG, Crone NE, et al. Serious and potentially life threatening complications of cardiac stress testing: Physiological mechanisms and management strategies. J Nucl Cardiol 2015;22:1198–213. doi:10.1007/s12350-015-0141-4. Rosenblatt J, Mooney D, Dunn T, Cohen M. Asystole following regadenoson infusion in stable outpatients. J Nucl Cardiol 2014;21:862–8. doi:10.1007/s12350-014-9898-0. Phillips L, Wang JW, Pfeffer B, Gianos E, Fisher D, Shaw LJ, et al. Clinical role of the Duke Activity Status Index in the selection of the optimal type of stress myocardial perfusion imaging study in patients with known or suspected ischemic heart disease. J Nucl Cardiol 2011;18:1015–20. doi:10.1007/s12350-011-9456-y. Murthy VL, Naya M, Foster CR, Hainer J, Gaber M, Di Carli G, et al. Improved cardiac risk assessment with noninvasive measures of coronary flow reserve. Circulation 2011;124:2215–24. doi:10.1161/CIRCULATIONAHA.111.050427.